GATTI, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 1.274
EU - Europa 523
AS - Asia 180
AF - Africa 13
SA - Sud America 6
OC - Oceania 1
Totale 1.997
Nazione #
US - Stati Uniti d'America 1.262
IT - Italia 117
UA - Ucraina 113
SE - Svezia 104
IN - India 70
CN - Cina 57
SG - Singapore 51
FI - Finlandia 48
NL - Olanda 39
GB - Regno Unito 33
DE - Germania 24
TG - Togo 13
IE - Irlanda 12
CA - Canada 10
BE - Belgio 9
AR - Argentina 6
BG - Bulgaria 6
FR - Francia 6
RO - Romania 6
GR - Grecia 2
MX - Messico 2
PL - Polonia 2
AZ - Azerbaigian 1
CH - Svizzera 1
ES - Italia 1
IR - Iran 1
NZ - Nuova Zelanda 1
Totale 1.997
Città #
Woodbridge 164
Fairfield 120
Chandler 108
Ann Arbor 100
Ashburn 82
Houston 59
Dearborn 56
Wilmington 45
Seattle 43
Jacksonville 40
Princeton 36
Plano 35
Cambridge 32
Singapore 29
Beijing 27
Milan 23
Des Moines 20
Boston 19
Riverside 16
Boardman 15
Lawrence 15
Helsinki 14
Lomé 13
San Diego 12
San Paolo di Civitate 12
Dublin 11
Maserada Sul Piave 10
Brussels 9
Lendinara 9
Rome 9
San Mateo 9
Auburn Hills 8
Bremen 8
Fremont 8
Millbury 8
Toronto 8
Andover 7
Federal 6
Nanjing 6
New York 6
Norwalk 6
Pune 6
Sofia 6
Southend 6
Colleferro 3
Hefei 3
Los Angeles 3
Mannheim 3
Nanchang 3
Parma 3
Rovigo 3
Buffalo 2
Bühl 2
Chieti 2
Chongqing 2
Falls Church 2
Ottawa 2
Santa Maria A Monte 2
Trento 2
Wilmslow 2
Xian 2
Zhengzhou 2
Baku 1
Basking Ridge 1
Berlin 1
Bern 1
Changsha 1
Coacalco 1
Cork 1
Frankfurt am Main 1
Guangzhou 1
Hangzhou 1
Hebei 1
Henderson 1
Jinan 1
Kiev 1
Leawood 1
Madrid 1
Mexico City 1
Nogaredo 1
Padova 1
Palermo 1
Polverara 1
San Francisco De Las Llagas 1
Sant'elpidio A Mare 1
Shenyang 1
Shenzhen 1
Springfield 1
Taiyuan 1
Tappahannock 1
Terni 1
Thessaloniki 1
Trumbull 1
Washington 1
Wellington 1
Totale 1.357
Nome #
L’attività ossidante dei monociti circolanti è aumentata in pazienti con diabete di tipo 2 e disfunzione erettile. 162
A case of severe occult ectopic adrenocorticotropin syndrome treated with retrograde venous adrenal ablation using ethanol 116
Antioxidant treatment associated to sildenafil reduces monocyte activation an markers of endothelial damage in patients with diabetes and erectyle dysfunction. 102
Circulating monocyte oxidative activity is increased in patients with type 2 diabetes and erectile dysfunction 86
Antioxidant treatment associated to sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study 81
Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. 75
Effect of insulin on airway responsiveness in patients with type 2 diabetes mellitus: A cohort study 72
Vascular Endothelial Growth Factor plasma levels are not correlated to renal dysfunction in patients with type 2 diabetes and hypertension. 64
Atorvastatin downregulates monocyte CD36 expression, nuclear NFkB levels and TNFalfa production in type 2 diabetes. 64
Cardiovascular effects of chronic sildenafil treatment in men with type 2 diabetes 62
In pazienti diabetici l’escrezione urinaria di VEGF è correlata all’albuminuria. 61
Effetti Cardiovascolari della Somministrazione in Cronico di Sildenafil in Soggetti con ?Diabete Mellito di tipo 2 61
L’attivita’ ossidante dei monociti circolanti e’ aumentata in pazienti diabetici con disfunzione erettile 61
Atorvastatin Downregulates Monocyte CD36 Expression, Nuclear NF kappa B and TNF alpha Levels in Type 2 Diabetes 59
Metabolic syndrome is not a risk factor for kidney dysfunction in obese non-diabetic subjects 57
Prevalenza di bassi livelli di colesterolo HDL e correlazione con il grado di controllo glicometabolico in pazienti con diabete di tipo 2. 55
Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH 55
Poor Glycemic Control Is an Independent Risk Factor for Low HDL Cholesterol in Patients With Type 2 Diabetes 55
Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients 55
Aumentata espressione di poly-ADP ribosio polymerasi in mononucleati circolanti di pazienti con diabete di tipo 2 50
The metabolic syndrome and insulin resistance are not risk factors for chronic kidney disease in obese non diabetic subjects. 50
Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study 50
Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2 50
Atorvastatin downregulates monocyte CD36 scavenger receptor expression and nuclear NFkB levels in type 2 diabetic patients. 49
The metabolic sindrome is not a risk factor for reduced kidney function in obese non diabetic subjects. 46
Waist circumference reduction after insulin Detemir therapy in type 2 diabetes patients previously treated with NPH. 46
Identificazione e caratterizzazione di proteine poly(ADP-ribosil)ate in mononucleati circolanti di diabetici di tipo 2 mediante proteomica. 42
The impairment of renal function is not associated to altered circulating vascular endothelial growth factor in patients with Type 2 diabetes and hypertension. 40
Sindrome metabolica e disfunzione erettile in una popolazione di pazienti obesi non diabetici. 39
Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues 37
Does intervention on glycemic control influence HDL cholesterol levels in type 2 diabetes? A pilot study 32
La disfunzione erettile e i disturbi sessuali nel diabete 31
Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: A further experimental insight into the pathophysiology of diabetic nephropathy 28
Effetti del trattamento con atorvastatina sull'espressione del CD36 e sui livelli di NFkB nucleare in monociti circolanti di pazienti con diabete di tipo 2. 28
VENTRICULAR REMODELING IN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION: ROLE OF VEGF. 25
Totale 2.046
Categoria #
all - tutte 5.034
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.034


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020359 0 14 8 30 23 89 56 47 36 32 15 9
2020/2021209 21 17 4 12 4 23 40 12 17 22 32 5
2021/2022371 9 21 38 21 48 14 6 28 25 29 69 63
2022/2023401 77 58 30 42 50 58 11 13 43 0 19 0
2023/2024176 15 26 3 13 18 35 1 19 2 14 10 20
2024/202544 39 5 0 0 0 0 0 0 0 0 0 0
Totale 2.046